Fig. 7: FADS1 predicts a poor prognosis in CRC.
a The mRNA expression of FADS1 in NC (n = 13 samples), Ad (n = 50 samples), and CRC (n = 25 samples) samples from GSE41657 (means ± s.d.; two-tailed unpaired t test), NC: normal colon epithelial tissue, Ad: colon adenoma, CRC: colorectal cancer. **p = 0.008, 0.007. b Kaplan–Meier analysis of the relationship between the FADS1 mRNA expression and prognosis of CRC patients from the TCGA dataset, FADS1-low: CRC patients with a low mRNA expression of FADS1 (n = 220), FADS1-high: CRC patients with a high mRNA expression of FADS1 (n = 220). p value showed the statistical difference. c. Representative images of IHC staining of the FADS1 expression in matched NC, Ad, and CRC tissues (n = 6 samples per group, one-way repeated-measures ANOVA), NC: normal colon epithelial tissue, Ad: colon adenoma, CRC: colorectal cancer. IHC score was divided into Low and High groups, Low, score 1 or 2, High, score 3 or 4. *p = 0.029. d Representative images of IHC staining of the FADS1 expression in CRC and adjacent non-cancerous tissues of the tissue microarray (392 cases). Scale bars, 100 μm. e Representative images of IHC staining of the FADS1 expression in CRC tissues with different pathological stages. Scale bars, 100 μm. f Correlation between the pathological stage and FADS1 expression in CRC and adjacent non-cancerous tissues of the tissue microarray (392 cases). Both variables are hierarchical data and rank sum test was used to statistical analysis. p = 0.034. g Kaplan–Meier analysis of the relationship between the FADS1 protein expression and prognosis of CRC patients from the tissue microarray, FADS1-low: CRC patients with a low protein expression of FADS1 (n = 196), FADS1-high: CRC patients with a high protein expression of FADS1 (n = 196). p = 0.027. h Multivariate Cox regression analysis of clinicopathologic factors for the FADS1 expression applied in the Renji cohort (n = 392). HR, hazard ratio, 95% CI, 95% confidence interval. p = 0.001, 0.533, 0.919, 0.004, <0.001. i IVIS imaging of the orthotopic tumor treated with FADS1 inhibitor, D5D-IN-326 (2 mg/kg, p.o. for 2 weeks) (n = 6 mice per group, means ± s.d.; two-tailed unpaired t test). ***p < 0.001. Scale colour bar (SW480): 1×107−1×108, Scale colour bar (HCT-116): 1×107−5×108, Scale colour bar (organoid): 2.52×107−4.26×108. j Survival analysis of the mice burden with the orthotopic tumors treated with D5D-IN-326 (n = 6 mice per group, Kaplan–Meier analysis). p = 0.003, 0.008, 0.006. Source data are provided in the Source Data file.
